Mechanisms responsible for the termination of an inflammatory response include the activation of a genetic programme of cellular suicide termed apoptosis, which leads to the elimination of the cellular effectors of acute inflammation, particularly the neutrophil. However, delays in this response result in the persistence of inflammation and the development of inflammatory disorders. Understanding the mechanism that inhibits the process of cell death may be helpful in the treatment of inflammatory disorders. Inflammatory cytokines have been shown to inhibit apoptosis through stabilization of the mitochondria and inhibition of the caspase cascade. To date, how these processes are inhibited remains the central question. We hypothesize that the decision for the delay in neutrophil apoptosis is made through signals delivered on the cell surface, which activate combinations of specific genes that inhibit the cell death pathway. Gene chip microarray experiments were performed in in vivo and in vitro models of delayed neutrophil apoptosis. Analysis has yielded changes in a large number of genes involved in inflammation, metabolism, signalling, mitochondrial function and apoptosis. A number of genes have been identified as suitable targets responsible for the regulation of neutrophil apoptosis and their expression was confirmed by real-time PCR and explored at the level of the protein. Their functional role in the apoptotic response is now being determined. One significant finding is that the gene patterns of delay in vitro and in vivo appear to be different, indicating the possibility for different pathways regulating the delay in neutrophil apoptosis.
Introduction
The regulation of neutrophil apoptosis during an inflammatory response plays a critical role in its resolution [1] . Neutrophils release proteolytic enzymes and reactive oxygen intermediates, which help in eliminating bacterial infections, but also cause extensive tissue damage. These inflammatory neutrophils are cleared from the site of infection by the process of apoptosis [2] . The development of inflammatory disorders, such as acute pancreatitis [3] , inflammatory bowel disease [4] , acute respiratory distress syndrome and the SIRS (systemic inflammatory response syndrome) [5] , is associated with the accumulation of activated neutrophils due in part to a delay in the apoptotic process. The inability of the body to resolve an inflammatory response can be detrimental; therefore, understanding the mechanisms for delayed neutrophil apoptosis has important clinical implications [6, 7] .
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microarrays to identify gene profiles of the neutrophils induced to die via the FcR-and CR-mediated phagocytosis pathway. They identified changes in more than 30 genes involved in at least three apoptotic pathways, indicating the importance of gene expression in the regulation of neutrophil apoptosis and in the identification of specific pathways, including the involvement of the caspase cascade [16] . The caspase cascade represents the main death pathway and is activated by both the intrinsic (receptor-mediated) and extrinsic (mitochondrial-mediated) pathways. The caspases are initially synthesized as an inactive precursor or zymogen, which requires proteolytic cleavage to the active enzyme [8] . Previous studies have demonstrated cleavage and increased activity of the caspases in spontaneous [9] , Fas antibodyinduced [10] and TNFα (tumour necrosis factor α)-induced [11] neutrophil apoptosis. Triggering of neutrophil apoptosis via the mitochondria still remains unknown, but increasing evidence points to the release of cytochrome c, even though at very low levels, activating an extremely sensitive apoptosome [12] . Since the mitochondrial/caspase pathway is an important axis for the induction of neutrophil apoptosis, it was an interesting target to focus on to determine the mechanisms for delayed apoptosis.
In line with this hypothesis, our laboratory has shown that delayed neutrophil apoptosis induced by inflammatory or other mediators is associated with the inhibition of caspase activation ( [10, 13] ; also see [14] ). The mechanisms associated with caspase inhibition and delayed apoptosis still remain unknown, but numerous proteins have been shown to regulate the apoptotic process, including the Bcl-2 and the IAP (inhibitor of apoptosis) family of proteins. It has been shown that Mcl-1 and A1 are associated with delayed neutrophil apoptosis [15] , representing proteins that could stabilize the mitochondrial membrane. In addition, LPS (lipopolysaccharide) and GM-CSF (granulocyte/macrophage colony-stimulating factor) have been shown to stabilize the mitochondrial membrane induced by Fas-antibody-induced neutrophil apoptosis [10] . These studies suggest that inhibition of the mitochondrial/caspase axis is important in delaying apoptosis. However, inhibition may not also be required, since neutrophils isolated from patients with inflammatory complications associated with delayed apoptosis show a significant decrease in the basal pro-caspase expression [3, 4] . This loss of an essential pro-apoptotic protease may also contribute to the delay in neutrophil apoptosis. It is interesting to note that this alteration in caspase expression is not observed in normal neutrophils stimulated for a delay in their apoptotic response, indicating a difference in the mechanisms in vitro and in vivo.
Use of and rationale for gene chip experiments
Because of the complexity in determining the mechanisms for delayed apoptosis, a gene chip microarray/bioinformatics approach was used to determine the mechanisms for delayed neutrophil apoptosis in the hope that it would reveal patterns of genes associated with delayed apoptosis in vitro and in vivo. This new approach would also help us to identify both unassuming factors and novel genes that might not have been hypothesized to be involved in this process.
We hypothesized that the biological decision for the delay in neutrophil apoptosis is made through signals delivered on the cell surface, which activate combinations of specific genes and proteins that inhibit the cell death pathway.
Initially, the following four groups of neutrophils were studied in duplicate by Affymetrix gene chips: (1) control neutrophils, (2) neutrophils stimulated with LPS, (3) neutrophils isolated from patients with SIRS [The patient selection was based on specific criteria stated in the APACHE II scoring system: temperature 38
• C or 35.6
• C, tachycardia 20 breaths/min or requiring mechanical ventilation, tachycardia 90 beats/min (in the presence of β blockade/cardiac pacemaker, this criteria will be considered fulfilled) and leucocytes >12 or <4, or >10% immature band forms. Patients fulfilled all the criteria within 24 h, at which time blood was collected.] and (4) control neutrophils stimulated with a mixture of plasma from the patients. Informed consent was obtained from all the patients and volunteers recruited either as controls or patients from the Intensive Care Unit of the Mater Misericordiae University Hospital in accordance with the ethical approval obtained from the Ethics Committee.
As has been demonstrated in a previous neutrophil gene expression analysis [16] [17] [18] , there was a significant number of genes regulated in the neutrophils.
Importance of methodology when undertaking GeneChip microarrays

Neutrophil purification
Use of this highly sensitive technique requires high purity of neutrophils, so that contaminating cells such as lymphocytes do not result in misinterpretation of the results. For this reason, we have used neutrophils that have undergone two Ficoll density centrifugations, resulting in a purity of 98% neutrophils as confirmed by flow cytometry and staining with an array of neutrophil and lymphocyte markers. However, we have now moved to neutrophils isolated by sorting on a FACSAria cell sorter to obtain neutrophils with 100% purity.
RNA isolation and GeneChip microarrays
Details of sample preparation and array processing are available from Affymetrix UK (High Wycombe, Bucks., U.K.). Briefly, total RNA was extracted from isolated neutrophils using TRIzol R (Invitrogen Life Technologies, Paisley, Renfrewshire, U.K.) and purified using a Qiagen RNeasy Mini kit (Qiagen, Crawley, West Sussex, U.K.) according to the manufacturer's instructions. Total RNA (5 µg) was used to prepare double-stranded cDNA (Superscript; Invitrogen Life Technologies) with a T7-(dT) 24 primer containing a T7 RNA polymerase promoter site (Sigma-GenoSys, SigmaAldrich, Poole, Dorset, U.K.). Biotinylated complementary RNA was made from approx. 16 µg of cDNA (Enzo BioArray TM high-yield RNA transcript labelling kit; Enzo Diagnostics, NY, U.K.) and then fragmented to approx. 50-100 nucleotides. In vitro transcripts (10 µg) with appropriate controls and spikes were hybridized to an Affymetrix U95A array (Hu 12 000) for 16 h at 45
• C with constant rotation at 60 rev./min. Chips were washed and stained by the Euk1V2 method on an Affymetrix Fludicis station. The stain included streptavidin-phycoerythrin (10 µg/ml; Molecular Probes) and biotinylated goat antistreptavidin (3 µg/ml; Vector Laboratories, Peterborough, U.K.). Chips were scanned with an HP argon laser confocal microscope, with emission at 488 nm and detection at 570 nm. Fluorescence intensity was standardized to 900 so that both chips could be directly compared.
Computational analysis
Genes were defined as differentially transcribed if the average expression level increased at least 2-fold compared with the control, which was carried out by GeneChip Suite TM (Affymetrix). Lists of differentially regulated genes were then analysed by a number of techniques, including manual analysis and the use of GeneSpring expression software, version 4.04. Early growth response protein 1 +3.9
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Ste20-like kinase (MST2) +2.9
Serine proteinase inhibitor (P19) +15.3
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A number of reports have now been published demonstrating gene expression profiles for neutrophils undergoing apoptosis or neutrophils stimulated for a delay in apoptosis [16] [17] [18] . However, so far, all experiments have been performed with normal control neutrophils stimulated to undergo or inhibit the apoptotic response.
Our initial experiments focused on models that delay neutrophil apoptosis: both in vitro, using LPS [19] , and in vivo, using neutrophils isolated from patients with SIRS [5] . These studies revealed that, in normal controls, neutrophils stimulated for a delay in apoptosis with either LPS or plasma isolated from SIRS patients had similar changes in the genes associated with delayed apoptosis (Table 1) . From these experiments, Cox-2 (cyclo-oxygenase-2) and two members of the IAP family (c-IAP-1 and c-IAP-2) were chosen for further studies. Cox-2 was associated with delayed apoptosis in the in vivo SIRS model of delayed apoptosis, but in vitro manipulation of the functional activity of Cox-2 did not alter the delay in neutrophil apoptosis. c-IAP-1 and c-IAP-2 were not increased in the neutrophils of septic patients who expressed a different set of anti-apoptotic proteins that might contribute to their delay in apoptosis, most notably, an increase in XIAP and a decrease in XIAP-associated protein, which binds to and inhibits XIAP activity. The IAP family, which consists of eight human homologues, c-IAP-1, c-IAP-2, XIAP, NAIP, Survivin, ML-IAP, hILP-2 and Apollon [20] [21] [22] [23] [24] [25] [26] [27] , represents an interesting family of anti-apoptotic proteins, since they interfere with the mitochondrial/caspase axis, highlighted as a site where inhibition might occur. They contain BIR (baculovirus inhibitory repeat) domains that are 70 amino acids in size, with a core sequence of cysteine and histidine residues. These BIR domains and their linker regions are involved in the inhibition of the caspase activity [28, 29] . XIAP, NAIP, c-IAP-1 and c-IAP-2 have three BIR domains and Survivin and Apollon have one [30, 31] . The main function of IAPs is to bind to and inhibit the activation of the caspases, in-particular caspases 3, 7 and 9. The expressions of c-IAP-1 and c-IAP-2 are regulated by TNFα through the TNFR (TNF receptor) I and II receptors, indicating an antiapoptotic signalling mechanism for TNFα [32] .
Although most of the inflammatory gene expression profiles were similar between the in vitro and in vivo groups, the only other group of genes that were differentially expressed was the neutrophil differentiation markers, which were altered in the in vivo model with no change in the in vitro model (Table 1) .
These findings have led us to believe that the mechanisms for delayed apoptosis stimulated in normal neutrophils by inflammatory cytokines are different from neutrophils isolated from patients undergoing an inflammatory response with a corresponding delay in their cell-death pathway. We would hypothesize that these in vivo neutrophils have an additional factor contributing to their delay, which might be explained by the premature release of neutrophils from the bone marrow with an immature phenotype. This, in combination with the additional exposure to inflammatory mediators, may alter the overall anti-apoptotic phenotype of the neutrophil. Identification of genes that contribute to an altered in vivo phenotype is important if therapeutic approaches are to be directed towards the relevant in vivo model of delayed apoptosis and inflammation.
